FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117134611> ?p ?o ?g. }

• W2117134611 endingPage "2276" @default.
• W2117134611 startingPage "2269" @default.
• W2117134611 abstract "To investigate the efficacy and tolerability of galantamine, using a slow dose escalation schedule of up to 8 weeks, in 978 patients with mild to moderate AD.A 5-month multicenter, placebo-controlled, double-blind trial. Following a 4-week placebo run-in, patients were randomized to one of four treatment arms: placebo or galantamine escalated to final maintenance doses of 8, 16, or 24 mg/day. Outcome measures included the cognitive subscale of the AD Assessment Scale (ADAS-cog), the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), the AD Cooperative Study Activities of Daily Living inventory, and the Neuropsychiatric Inventory. Standard safety evaluations and adverse event monitoring were carried out.After 5 months, the galantamine-placebo differences on ADAS-cog were 3.3 points for the 16 mg/day group and 3.6 points for the 24 mg/day group (p < 0.001 versus placebo, both doses). Compared with placebo, the galantamine 16- and 24-mg/day groups also had a significantly better outcome on CIBIC-plus, activities of daily living, and behavioral symptoms. Treatment discontinuations due to adverse events were low in all galantamine groups (6 to 10%) and comparable with the discontinuation rate in the placebo group (7%). The incidence of adverse events in the galantamine groups, notably gastrointestinal symptoms, was low and most adverse events were mild.Galantamine 16 and 24 mg/day significantly benefits the cognitive, functional, and behavioral symptoms of AD as compared with placebo. Slow dose escalation appears to enhance the tolerability of galantamine, minimizing the incidence and severity of adverse events." @default.
• W2117134611 created "2016-06-24" @default.
• W2117134611 creator A5002451678 @default.
• W2117134611 creator A5004801944 @default.
• W2117134611 creator A5005943180 @default.
• W2117134611 creator A5008043878 @default.
• W2117134611 creator A5023626549 @default.
• W2117134611 creator A5050036233 @default.
• W2117134611 date "2000-06-27" @default.
• W2117134611 modified "2023-10-17" @default.
• W2117134611 title "A 5-month, randomized, placebo-controlled trial of galantamine in AD" @default.
• W2117134611 cites W1164896577 @default.
• W2117134611 cites W1491337017 @default.
• W2117134611 cites W1847168837 @default.
• W2117134611 cites W1953027527 @default.
• W2117134611 cites W1980525435 @default.
• W2117134611 cites W1991176470 @default.
• W2117134611 cites W1993818042 @default.
• W2117134611 cites W1994067502 @default.
• W2117134611 cites W1996776294 @default.
• W2117134611 cites W2016659621 @default.
• W2117134611 cites W2033610699 @default.
• W2117134611 cites W2035663078 @default.
• W2117134611 cites W2057679568 @default.
• W2117134611 cites W2066501757 @default.
• W2117134611 cites W2069284334 @default.
• W2117134611 cites W2078919465 @default.
• W2117134611 cites W2085443670 @default.
• W2117134611 cites W2089223747 @default.
• W2117134611 cites W2095477109 @default.
• W2117134611 cites W2097885652 @default.
• W2117134611 cites W2105233285 @default.
• W2117134611 cites W2111963393 @default.
• W2117134611 cites W2122692162 @default.
• W2117134611 cites W2137777161 @default.
• W2117134611 cites W2141997991 @default.
• W2117134611 cites W2156220037 @default.
• W2117134611 cites W2253878725 @default.
• W2117134611 cites W2315512533 @default.
• W2117134611 doi "https://doi.org/10.1212/wnl.54.12.2269" @default.
• W2117134611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10881251" @default.
• W2117134611 hasPublicationYear "2000" @default.
• W2117134611 type Work @default.
• W2117134611 sameAs 2117134611 @default.
• W2117134611 citedByCount "848" @default.
• W2117134611 countsByYear W21171346112012 @default.
• W2117134611 countsByYear W21171346112013 @default.
• W2117134611 countsByYear W21171346112014 @default.
• W2117134611 countsByYear W21171346112015 @default.
• W2117134611 countsByYear W21171346112016 @default.
• W2117134611 countsByYear W21171346112017 @default.
• W2117134611 countsByYear W21171346112018 @default.
• W2117134611 countsByYear W21171346112019 @default.
• W2117134611 countsByYear W21171346112020 @default.
• W2117134611 countsByYear W21171346112021 @default.
• W2117134611 countsByYear W21171346112022 @default.
• W2117134611 countsByYear W21171346112023 @default.
• W2117134611 crossrefType "journal-article" @default.
• W2117134611 hasAuthorship W2117134611A5002451678 @default.
• W2117134611 hasAuthorship W2117134611A5004801944 @default.
• W2117134611 hasAuthorship W2117134611A5005943180 @default.
• W2117134611 hasAuthorship W2117134611A5008043878 @default.
• W2117134611 hasAuthorship W2117134611A5023626549 @default.
• W2117134611 hasAuthorship W2117134611A5050036233 @default.
• W2117134611 hasConcept C126322002 @default.
• W2117134611 hasConcept C142724271 @default.
• W2117134611 hasConcept C15744967 @default.
• W2117134611 hasConcept C168563851 @default.
• W2117134611 hasConcept C197934379 @default.
• W2117134611 hasConcept C204787440 @default.
• W2117134611 hasConcept C27081682 @default.
• W2117134611 hasConcept C2778375690 @default.
• W2117134611 hasConcept C2779056891 @default.
• W2117134611 hasConcept C2779134260 @default.
• W2117134611 hasConcept C2779483572 @default.
• W2117134611 hasConcept C2780904820 @default.
• W2117134611 hasConcept C42219234 @default.
• W2117134611 hasConcept C71924100 @default.
• W2117134611 hasConceptScore W2117134611C126322002 @default.
• W2117134611 hasConceptScore W2117134611C142724271 @default.
• W2117134611 hasConceptScore W2117134611C15744967 @default.
• W2117134611 hasConceptScore W2117134611C168563851 @default.
• W2117134611 hasConceptScore W2117134611C197934379 @default.
• W2117134611 hasConceptScore W2117134611C204787440 @default.
• W2117134611 hasConceptScore W2117134611C27081682 @default.
• W2117134611 hasConceptScore W2117134611C2778375690 @default.
• W2117134611 hasConceptScore W2117134611C2779056891 @default.
• W2117134611 hasConceptScore W2117134611C2779134260 @default.
• W2117134611 hasConceptScore W2117134611C2779483572 @default.
• W2117134611 hasConceptScore W2117134611C2780904820 @default.
• W2117134611 hasConceptScore W2117134611C42219234 @default.
• W2117134611 hasConceptScore W2117134611C71924100 @default.
• W2117134611 hasIssue "12" @default.
• W2117134611 hasLocation W21171346111 @default.
• W2117134611 hasLocation W21171346112 @default.
• W2117134611 hasOpenAccess W2117134611 @default.
• W2117134611 hasPrimaryLocation W21171346111 @default.
• W2117134611 hasRelatedWork W1966047811 @default.

• next